Suppr超能文献

具有改善的人乙醚-a-去极化相关基因(hERG)和微粒体稳定性特征的反苯环丙胺衍生的赖氨酸特异性去甲基化酶1(LSD1)抑制剂的设计与合成

Design and Synthesis of Tranylcypromine-Derived LSD1 Inhibitors with Improved hERG and Microsomal Stability Profiles.

作者信息

Koda Yasuko, Sato Shin, Yamamoto Hirofumi, Niwa Hideaki, Watanabe Hisami, Watanabe Chiduru, Sato Tomohiro, Nakamura Kana, Tanaka Akiko, Shirouzu Mikako, Honma Teruki, Fukami Takehiro, Koyama Hiroo, Umehara Takashi

机构信息

Drug Discovery Chemistry Platform Unit, Drug Discovery Seed Compounds Exploratory Unit, Chemical Genomics Research Group, RIKEN Center for Sustainable Resource Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.

Laboratory for Epigenetics Drug Discovery, RIKEN Center for Biosystems Dynamics Research, 1-7-22 Suehiro-cho, Tsurumi, Yokohama 230-0045, Japan.

出版信息

ACS Med Chem Lett. 2022 Apr 29;13(5):848-854. doi: 10.1021/acsmedchemlett.2c00120. eCollection 2022 May 12.

Abstract

Lysine-specific demethylase 1 (LSD1/KDM1A) is a promising therapeutic target for the treatment of cancers. Several derivatives of tranylcypromine (2-phenylcyclopropylamine) have been developed as LSD1 inhibitors. One such derivative is ; however, this compound has a high hERG channel inhibitory activity and a low microsomal stability, making it unsuitable as a drug candidate. Here, using an hERG inhibition prediction model, we designed, synthesized, and evaluated a novel series of derivatives characterized by modifications of the benzyloxy and piperazine groups. Among the synthesized derivatives, a compound possessing 2-fluoropyridine and 2,8-diaza-spiro[4.5]decane groups (compound ) showed the most desirable activities, and its eutomer, , was isolated by the optical resolution of . In addition to potent LSD1 inhibitory activity, exhibited desirable hERG channel inhibition and microsomal stability profiles.

摘要

赖氨酸特异性去甲基化酶1(LSD1/KDM1A)是一种很有前景的癌症治疗靶点。反苯环丙胺(2-苯基环丙胺)的几种衍生物已被开发为LSD1抑制剂。其中一种衍生物是 ;然而,该化合物具有较高的人乙醚相关基因(hERG)通道抑制活性和较低的微粒体稳定性,使其不适宜作为候选药物。在此,我们使用hERG抑制预测模型,设计、合成并评估了一系列以苄氧基和哌嗪基团修饰为特征的新型衍生物。在合成的衍生物中,一种具有2-氟吡啶和2,8-二氮杂螺[4.5]癸烷基团的化合物(化合物 )表现出最理想的活性,其优映体 通过 的光学拆分被分离出来。除了具有强大的LSD1抑制活性外, 还表现出理想的hERG通道抑制和微粒体稳定性特征。

相似文献

1
Design and Synthesis of Tranylcypromine-Derived LSD1 Inhibitors with Improved hERG and Microsomal Stability Profiles.
ACS Med Chem Lett. 2022 Apr 29;13(5):848-854. doi: 10.1021/acsmedchemlett.2c00120. eCollection 2022 May 12.
3
Development and Structural Evaluation of N-Alkylated trans-2-Phenylcyclopropylamine-Based LSD1 Inhibitors.
ChemMedChem. 2020 May 6;15(9):787-793. doi: 10.1002/cmdc.202000014. Epub 2020 Mar 30.
4
Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment.
Eur J Med Chem. 2023 May 5;251:115228. doi: 10.1016/j.ejmech.2023.115228. Epub 2023 Feb 23.
5
Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Eur J Med Chem. 2017 Nov 10;140:392-402. doi: 10.1016/j.ejmech.2017.09.038. Epub 2017 Sep 21.
6
Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
J Med Chem. 2020 Dec 10;63(23):14197-14215. doi: 10.1021/acs.jmedchem.0c00919. Epub 2020 Sep 30.
7
TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy.
Epigenomics. 2016 May;8(5):651-66. doi: 10.2217/epi-2015-0002. Epub 2016 Apr 22.
8
Novel spirocyclic tranylcypromine derivatives as lysine-specific demethylase 1 (LSD1) inhibitors.
RSC Adv. 2018 Jan 5;8(3):1666-1676. doi: 10.1039/c7ra13097j. eCollection 2018 Jan 2.
10
Design, synthesis and in vitro/in vivo anticancer activity of tranylcypromine-based triazolopyrimidine analogs as novel LSD1 inhibitors.
Eur J Med Chem. 2023 May 5;253:115321. doi: 10.1016/j.ejmech.2023.115321. Epub 2023 Mar 30.

引用本文的文献

2
The multifaceted role of post-translational modifications of LSD1 in cellular processes and disease pathogenesis.
Genes Dis. 2024 Apr 15;12(3):101307. doi: 10.1016/j.gendis.2024.101307. eCollection 2025 May.
3
Novel pharmacologic inhibition of lysine-specific demethylase 1 as a potential therapeutic for glioblastoma.
Cancer Gene Ther. 2024 Dec;31(12):1884-1894. doi: 10.1038/s41417-024-00847-8. Epub 2024 Nov 5.
4
Virtual Special Issue: Epigenetics 2022.
ACS Pharmacol Transl Sci. 2022 Sep 9;5(10):829-834. doi: 10.1021/acsptsci.2c00169. eCollection 2022 Oct 14.
5
Virtual Special Issue: Epigenetics 2022.
ACS Med Chem Lett. 2022 Oct 13;13(10):1524-1529. doi: 10.1021/acsmedchemlett.2c00393.
6
Structure-Activity Relationship and Evaluation of - and -PCPA-Derived Inhibitors of LSD1 and LSD2.
ACS Med Chem Lett. 2022 Aug 18;13(9):1485-1492. doi: 10.1021/acsmedchemlett.2c00294. eCollection 2022 Sep 8.

本文引用的文献

2
Development and Structural Evaluation of N-Alkylated trans-2-Phenylcyclopropylamine-Based LSD1 Inhibitors.
ChemMedChem. 2020 May 6;15(9):787-793. doi: 10.1002/cmdc.202000014. Epub 2020 Mar 30.
5
Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor.
Clin Cancer Res. 2019 Mar 1;25(5):1601-1611. doi: 10.1158/1078-0432.CCR-18-0919. Epub 2018 Dec 5.
6
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.
Cancer Cell. 2018 Mar 12;33(3):495-511.e12. doi: 10.1016/j.ccell.2018.02.002. Epub 2018 Mar 1.
7
Lysine-specific demethylase 1 inhibitors prevent teratoma development from human induced pluripotent stem cells.
Oncotarget. 2018 Jan 8;9(5):6450-6462. doi: 10.18632/oncotarget.24030. eCollection 2018 Jan 19.
9
Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases.
Epigenetics. 2017 May 4;12(5):340-352. doi: 10.1080/15592294.2017.1290032. Epub 2017 Feb 10.
10
Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1.
PLoS One. 2017 Feb 3;12(2):e0170301. doi: 10.1371/journal.pone.0170301. eCollection 2017.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验